Defense Advanced Research Projects AgencyTagged Content List

Infectious Disease

Relating to ailments caused by pathogens

Showing 10 results for Disease + COVID-19 RSS
The Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program supports individual troop readiness and total force health protection by developing technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. A subset of ADEPT technologies specifically support use by personnel with minimal medical training, delivering centralized laboratory capabilities even in the low-resource environments typical of many military operations. The program is part of a portfolio of DARPA-funded research aimed at providing options for preempting or mitigating constantly evolving infectious disease threats.
The DoD requires timely and comprehensive threat detection to support overall readiness, counter the spread of disease, and promote stabilization missions. State of the art diagnostic and biosurveillance systems are unable to keep pace with disease outbreaks and fail to support decision-making at the time and place of need. The “Detect It with Gene Editing Technologies” (DIGET) program aims to leverage advances in gene editing technologies to develop field-forward diagnostic and biosurveillance technologies that enable detection of any threat, anytime, anywhere.
The Friend or Foe program aims to develop biosurveillance technology that can detect bacterial pathogens as, or even before, they threaten the military and homeland. The goal of the program is to quickly determine whether an unknown bacterium is harmless or virulent by directly identifying pathogenic behavior, avoiding conventional strategies that rely on known biomarkers.
Viral pathogens pose a continuous and shifting biological threat to military readiness and national security overall in the form of infectious disease with pandemic potential. Today’s limited vaccines and other antivirals are often circumvented by quickly mutating viruses that evolve to develop resistance to treatments that are carefully formulated to act only specific strains of a virus.
The Nucleic acids On-demand Worldwide (NOW) program aims to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to rapidly produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA).